v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Apr. 03, 2026
Jan. 02, 2026
Current assets:    
Cash and cash equivalents $ 226,152 $ 482,488
Marketable securities 551,055 576,603
Trade receivables, net 328,947 286,916
Inventory 26,605 21,686
Prepaid expenses and other current assets 75,878 75,596
Total current assets 1,208,637 1,443,289
Non-current marketable securities 649,144 603,603
Property and equipment, net 95,524 98,960
Deferred tax assets, net 293,730 292,582
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 282,874 342,305
Total assets 2,593,593 2,844,423
Current liabilities:    
Accounts payable 24,154 29,623
Accrued compensation and benefits 87,512 102,218
Accrued clinical trial liabilities 64,804 65,742
Rebates and fees due to customers 65,892 59,896
Accrued collaboration liabilities 28,327 22,783
Other current liabilities 100,286 125,382
Total current liabilities 370,975 405,644
Non-current operating lease liabilities 169,541 173,038
Other non-current liabilities 117,329 104,422
Total liabilities 657,845 683,104
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 253,701 and 262,483 at March 31, 2026, and December 31, 2025, respectively 254 262
Additional paid-in-capital 2,151,703 2,234,411
Accumulated other comprehensive income (loss) (415) 3,476
Accumulated deficit (215,794) (76,830)
Total stockholders’ equity 1,935,748 2,161,319
Total liabilities and stockholders’ equity $ 2,593,593 $ 2,844,423